文献速递炎症性肠病

HLA DQA1*05与儿童克罗恩病抗肿瘤坏死因子治疗失败及抗药抗体产生风险

HLA DQA1*05 and Risk of Antitumor Necrosis Factor Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's Disease.
PubMed 文献 · Am J Gastroenterol · 2024-10-18

该研究分析了一项多中心前瞻性随机试验中年龄小于21岁的克罗恩病患者的库存血清,比较抗肿瘤坏死因子单药治疗与联合甲氨蝶呤。HLA DQA1*05阳性与治疗失败及抗药抗体产生呈非显著升高趋势,联合甲氨蝶呤可减轻但未消除这些风险。

要点

  • HLA DQA1*05阳性者治疗失败风险呈非显著升高趋势(HR 1.58,95%CI 0.95-2.62,P=0.08)。
  • HLA DQA1*05阴性且使用甲氨蝶呤者较阳性且用安慰剂者治疗失败更少(HR 0.31,95%CI 0.13-0.70,P=0.005)。
  • HLA DQA1*05阳性者抗药抗体产生呈非显著升高趋势(OR 1.96,95%CI 0.90-4.31,P=0.09)。

核心结论

  • 在开始抗肿瘤坏死因子治疗的儿童克罗恩病随机试验中,40%为HLA DQ-A1*05阳性,该阳性与治疗失败和抗药抗体风险升高趋势相关。
  • 加用口服甲氨蝶呤可减轻但未消除上述风险。
  • HLA DQ-A1*05是预后和风险分层的重要生物标志物。

研究设计与样本

  • 分析年龄小于21岁的克罗恩病患者库存血清,患者来自一项多中心前瞻性随机试验(Methotrexate Binary Therapy in practice临床结局研究),比较抗肿瘤坏死因子单药治疗与联合甲氨蝶呤。
  • 主要结局为指示治疗失败的复合因素,次要结局为抗药抗体产生。

主要发现

  • HLA DQA1*05阳性参与者治疗失败呈升高趋势但未达统计学显著(HR 1.58,95%CI 0.95-2.62,P=0.08)。
  • 按HLA DQA1*05和甲氨蝶呤与安慰剂分层后,HLA DQA1*05阴性且分配至甲氨蝶呤者较HLA DQA1*05阳性且使用安慰剂者治疗失败更少(HR 0.31,95%CI 0.13-0.70,P=0.005)。
  • HLA DQA1*05阳性参与者抗药抗体产生呈升高趋势但未达统计学显著(OR 1.96,95%CI 0.90-4.31,P=0.09)。
  • 进一步分层后,HLA DQA1*05阴性且分配至甲氨蝶呤者较HLA DQA1*05阳性且使用安慰剂者抗药抗体产生更少(OR 0.12,95%CI 0.03-0.55,P=0.008)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Human leukocyte antigen (HLA) DQA1*05 has been associated with the development of anti-drug antibodies (ADA) to tumor necrosis factor antagonists (anti-TNFα) and treatment failure among adults with Crohn's disease (CD). However, findings from other studies have been inconsistent with limited pediatric data. METHODS: We analyzed banked serum from patients with CD aged <21 years enrolled in clinical outcomes of Methotrexate Binary Therapy in practice, a multicenter, prospective randomized trial of anti-TNFα monotherapy vs combination with methotrexate. The primary outcome was a composite of factors indicative of treatment failure. The secondary outcome was ADA development. RESULTS: A trend toward increased treatment failure among HLA DQA1*05-positive participants was not significant (hazard ratio 1.58, 95% confidence interval [CI] 0.95-2.62; P = 0.08). After stratification by HLA DQA1*05 and by methotrexate vs placebo, patients who were HLA DQA1*05 negative and assigned to methotrexate experienced less treatment failures than HLA DQA1*05-positive patients on placebo (hazard ratio 0.31, 95% CI 0.13-0.70; P = 0.005). A trend toward increased ADA development among HLA DQA1*05-positive participants was not significant (odds ratio 1.96, 95% CI 0.90-4.31, P = 0.09). After further stratification, HLA DQA1*05-negative participants assigned to methotrexate were less likely to develop ADA relative to HLA DQA1*05-positive patients on placebo (odds ratio 0.12, 95% CI 0.03-0.55; P = 0.008). DISCUSSION: In a randomized trial of children with CD initiating anti-TNFα, 40% were HLA DQ-A1*05 positive, which was associated with a trend toward increased risk of both treatment failure and ADA. These risks were mitigated, but not eliminated, by adding oral methotrexate. HLA DQ-A1*05 is an important biomarker for prognosis and risk stratification.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Adler J, Galanko JA, Ammoury R, et al. HLA DQA1*05 and Risk of Antitumor Necrosis Factor Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's Disease. Am J Gastroenterol. 2024. PMID: 40315028. doi:10.14309/ajg.0000000000003135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。